What makes it different.
- Continuous reinterpretation.Every month, a quiet update: “Here's what we learned about you this month.” New variant associations, expanded gene panels, refined polygenic scores. The recurring value the incumbents don't offer.
- Genome plus biomarkers, synthesized. Nobody else integrates germline genetics with continuous wearable and lab data in one reasoning system. Laymen does, because it is the same service underneath. Your HOMA-IR reads differently when the system also knows your TCF7L2 risk allele.
- Action at the point of decision.“If a doctor prescribes codeine, show them this — your body metabolizes it poorly.” Useful the day it matters, not only the day you download the PDF.
- Clinical review where it matters. High-penetrance findings — BRCA1/2, Lynch syndrome, familial hypercholesterolemia, cardiomyopathies — are reviewed by a contracted genetic counselor before disclosure. Pharmacogenomics and polygenic risk scores go directly to you with careful framing.
- Price leadership. $299 beats Nucleus ($399) and includes the first year of Laymen Personal. The recurring subscription is the same $29/month Personal charges on its own.
How the kit works.
Order a saliva kit, mail it back in the prepaid sleeve, and we sequence your whole genome at 30x average coverage through a CLIA/CAP-accredited lab partner. That depth matters: 30x is the threshold above which variant calls become clinically reliable, and it's the standard the NIH's All of Us program uses for precision-medicine research. We do not run microarrays, imputation tricks, or targeted panels.
Sample-to-first-interpretation is roughly five weeks. From the moment results land, your sequence is available everywhere in Laymen Personal that your data shows up — every morning brief, every proactive message, every answer.
What the interpretation covers.
Your sequence is processed through a phased variant-calling pipeline, and the interpretation covers six domains today:
- Pharmacogenomics. CPIC-curated gene–drug interactions across more than 120 medications, including SSRIs, statins, warfarin, opioids, and common chemotherapy agents. The kind of information that should be in your chart before a prescription is written.
- Monogenic risk. The ACMG SF v3.2 list of medically-actionable findings — BRCA1/2, Lynch syndrome, cardiomyopathies, familial hypercholesterolemia, and more — with opt-in disclosure and a path to confirmatory testing via the lab partner.
- Polygenic risk scores. Calibrated scores for coronary artery disease, type 2 diabetes, atrial fibrillation, breast cancer, and a growing list of well-validated phenotypes. We show you the score, the cohort it was trained on, and the limits of what a number on a curve can tell you.
- Carrier status. Recessive conditions you may pass on, with clear language about what carrier status means and does not mean for your own health.
- Traits and metabolism. Caffeine clearance, lactase persistence, alcohol flush, fast/slow nicotine metabolism, vitamin D and folate handling — the everyday biology that shapes how your body responds to food and substances.
- Ancestry. Population structure inferred from modern reference panels, presented as continuous mixture rather than tribal labels.
Read once, learn forever.
Your DNA does not change. The science of how to read it does — every month, sometimes every week. A variant that is “uncertain” today becomes “benign” or “pathogenic” as ClinVar and the broader literature accumulate evidence. A polygenic score gets re-derived as biobanks publish larger cohorts. A new CPIC guideline adjusts a drug-gene flag.
Other testing companies sell you a snapshot. Laymen sells you the underlying file and a commitment to keep re-reading it. When the ACMG list expands, your sequence is re-scanned against the new list and you get a quiet notification. When a new statin gets a pharmacogenomic flag, your medication summary updates before your next refill.
Storage and control.
Your raw FASTQs and processed VCFs are encrypted at rest with per-account keys. Engineers cannot bulk-read genomes. You can export the full FASTQ at any time. You can delete it — and the deletion propagates through every backup window within thirty days, with a tamper-evident log you can use to prove the data is gone.
Regulatory posture.
Genome interpretation falls under FDA Clinical Decision Support considerations. The lab partnership is with a CLIA/CAP-accredited lab that owns the wet-lab certifications; Laymen owns the software and interpretation layer. An FDA Pre-Submission is planned before wider scale-up. Genetic counselors are contracted from day one for high-penetrance findings.
What it is not.
Genome interpretation is not a diagnosis. A pathogenic variant in a cancer-susceptibility gene is a probability, not a sentence. A polygenic score is a population-level estimate, not a personal prophecy. Everything surfaced routes back to the right human in the loop — your primary care doctor, a genetic counselor, a specialist — through a one-page summary you can hand them.
Laymen Genome is also not a prenatal screen, a paternity test, a forensic tool, or a wellness product in a lab coat. It is a clinical-grade read of your genome, made useful because the system around it never stops reading.
Pricing and availability.
$299 for the kit, which includes sequencing, interpretation, the first year of Laymen Personal, and all monthly reinterpretation updates. After year one, $29/month to keep Personal + Genome running — the same $29 Personal charges on its own.
Public availability is targeted for Q4 2026, pending the CLIA/CAP lab partnership and the FDA Pre-Submission filing. The waitlist is live now with a $29 refundable deposit to reserve your kit.